Article Versions Notes

Parisi MS, Leotta S, Romano A, Del Fabro V, Martino EA, Calafiore V, Giubbolini R, Markovic U, Leotta V, Di Giorgio MA, et al. Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Journal of Clinical Medicine. 2019; 8(10):1695. https://doi.org/10.3390/jcm8101695

Parisi, Marina Silvia, Salvatore Leotta, Alessandra Romano, Vittorio Del Fabro, Enrica Antonia Martino, Valeria Calafiore, Rachele Giubbolini, Uros Markovic, Valerio Leotta, Mary Ann Di Giorgio, and et al. 2019. "Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients" Journal of Clinical Medicine 8, no. 10: 1695. https://doi.org/10.3390/jcm8101695

Parisi, M. S., Leotta, S., Romano, A., Del Fabro, V., Martino, E. A., Calafiore, V., Giubbolini, R., Markovic, U., Leotta, V., Di Giorgio, M. A., Tibullo, D., Di Raimondo, F., & Conticello, C. (2019). Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients. Journal of Clinical Medicine, 8(10), 1695. https://doi.org/10.3390/jcm8101695